Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.38 |
| ▸ | NOS2 | P35228 | 7/20 | 0.38 |
| ▸ | NOS1 | P29475 | 6/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30915338 | 1.00 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL3637109 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL19028071 | 0.77 | GAA (0.32) | NOS3NOS2NOS1 | |
| SCHEMBL21287270 | 0.77 | NOS3 (0.41) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL29344172 | 0.77 | SMN1; SMN2 (0.50) | POLB | |
| SCHEMBL16093699 | 0.77 | NOS2 (0.44) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL29975682 | 0.77 | GAA (0.32) | NOS3NOS2NOS1 | |
| SCHEMBL22029192 | 0.74 | NOS3 (0.38) | NOS3NOS2NOS1BACE1PRMT5 | |
| SCHEMBL22029038 | 0.74 | NOS2 (0.37) | NOS3NOS2NOS1 | |
| SCHEMBL29344249 | 0.70 | NOS2 (0.37) | NOS3NOS2NOS1BACE1CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC | 2026-03-26 | — | — | US | disclosed |
| EP-4577214-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-115151532-B | Quinoxalindione derivatives as irreversible inhibitors of KRAS G12C muteins | 北京泰德制药股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-115151532-A | Quinoxalinedione derivatives as irreversible inhibitors of KRAS G12C muteins | 北京泰德制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021219090-A1 | QUINOXALINE DIONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITÉ DE STRASBOURG (FR) | 2021-07-22 | — | — | US | disclosed |
| EP-3749305-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | Université de Strasbourg (FR) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683660-A | Compounds and compositions for the treatment of pain | 斯特拉斯堡大学 | 2020-09-18 | — | — | CN | disclosed |
| WO-2019149965-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | UNIVERSITE DE STRASBOURG (FR) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221784-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ACHE, TRPV1, OPRL1 | NOS3 725/4885NOS2 1125/4885NOS1 1834/4885 |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | KRAS, NRAS, RASGRP1 | NOS3 3451/4885NOS2 3885/4885NOS1 2636/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NOS3 4599/4885NOS2 4639/4885NOS1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.